;

Quintiles News

Please select a press release from the list below, or filter and sort to find a specific press release.

Published Date: All 2016 2015 2014 2013 2012 2011
Press Release Feb 05, 2016
RESEARCH TRIANGLE PARK, N.C. – February 5, 2016 – Quintiles, the world’s largest biopharmaceutical services company, has been awarded the HR.com 2016 Leadership Excellence Award for Innovation in Deployment of Leadership Programs.    HR.com, the largest global social networking and resource site for HR professionals, is committed to providing a deeper understanding of the HR function for over 250,000 members. For more than 33 years, they have identified and recognized the top organizations that develop their leaders. This year’s awards had more than 4,500 companies apply with 600,000 people voting on their programs to provide the most comprehensive ratings ever produced. These prestigious leadership awards salute the world’s best leadership practitioners and highlight their roles in the...
Read More
Press Release Jan 18, 2016
RESEARCH TRIANGLE PARK, N.C.-- Quintiles Transnational Holdings Inc. (NYSE: Q) will release its fourth-quarter 2015 financial results Thursday, February 11, 2016 prior to its quarterly earnings call at 8:00 a.m. EST. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 710-5091 in the United States or +1 (706) 902-0591 outside the United States, approximately 15 minutes before the scheduled start of the call. An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EST on Thursday, February 11th. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies...
Read More
Press Release Dec 21, 2015
RESEARCH TRIANGLE PARK, N.C. – December 21, 2015 – Quintiles CEO Tom Pike will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 in San Francisco at the Westin St. Francis Hotel. The Quintiles presentation will begin at 3:30 p.m. (PST).  Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors.  An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes.  From advisory through operations, Quintiles is...
Read More
Press Release Dec 10, 2015
RESEARCH TRIANGLE PARK, N.C. – December 10, 2015 – Quintiles, the world’s largest provider of biopharmaceutical services, today announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines development strategy, regulatory strategy, market and patient access and commercial expertise, with in-depth therapeutic knowledge, a facilitated strategic-planning process, data analytics and modeling to deliver an integrated asset-development plan. IADP brings together cross-functional strategies and operational delivery to enable more informed decisions that speed market access, fulfill regulatory requirements and help optimize commercial potential. Potential assets that could benefit from this new offering include small molecule drugs,...
Read More
Press Release Nov 09, 2015
RESEARCH TRIANGLE PARK, N.C. – November 9, 2015 – Quintiles, the world’s largest biopharma services provider, has announced its contribution of enhancements to the ResearchKit framework which was designed by Apple to make it easy for researchers to gather data more frequently and more accurately from research participants using iPhone apps. ResearchKit enables participants to easily complete tasks or submit surveys right from an app and delivers a simple way to present participants with an interactive informed consent process. Quintiles contributed enhancements to the ResearchKit framework to provide developers with extensions that support additional capabilities which, in turn, will allow them to create more sophisticated application experiences. Quintiles plans to use these...
Read More
Press Release Nov 05, 2015
RESEARCH TRIANGLE PARK, N.C.– November 5, 2015 – Quintiles Founder Dr. Dennis Gillings, CBE, will retire from his position as Executive Chairman of Quintiles Transnational Holdings Inc. (NYSE: Q) at the end of this year, December 31, 2015. Dr. Gillings will remain on the Board as a director. The Board has appointed Jack M. Greenberg to serve as Chairman of the Board, effective January 1, 2016.  Dr. Gillings began performing biostatical analysis work for pharmaceutical companies with a single project in 1974 while still a professor of biostatistics at the University of North Carolina at Chapel Hill. That small consulting business, which would become Quintiles, began with a handful of staff working out of a trailer on the UNC campus. Quintiles was incorporated as a privately held company...
Read More
Press Release Nov 05, 2015
RESEARCH TRIANGLE PARK, N.C. – November 5, 2015 – Today, the Quintiles Transnational Holdings Inc. (the “Company”) Board of Directors increased the Company’s share repurchase authorization by $300 million for repurchase of the Company’s outstanding common stock. The share repurchase program does not obligate the Company to acquire any particular amount of common stock, has no end date, and may be modified, suspended, or discontinued at any time. The timing and amount of repurchases are determined by the Company’s management based on a variety of factors such as the market price of the Company’s common stock, the Company’s corporate requirements, and overall market conditions. Purchases of the Company’s common stock may be made in open market transactions effected through a broker-dealer...
Read More
Press Release Nov 03, 2015
RESEARCH TRIANGLE PARK, NC - Quintiles CEO Tom Pike will present at the Credit Suisse 2015 Healthcare Conference on Tuesday, November 10, 2015 in Phoenix at the Phoenician resort. The Quintiles presentation will begin at 10:30 a.m. (MST). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product...
Read More
Press Release Oct 30, 2015
RESEARCH TRIANGLE PARK, N.C. – October 30, 2015 – Quintiles, the world’s largest provider of product development and integrated healthcare services, today published new research that reveals high levels of patient satisfaction and engagement in clinical research. Based on a survey of U.S. clinical research patients, all of the respondents agreed that clinical research participation reduced their overall cost of healthcare and improved their interest/involvement in their overall health. In addition, 95 percent of survey participants said that participating in clinical research positively impacted their overall quality of care. “These findings illustrate the value of integrating clinical research into the traditional continuum of care,” said Jeanne Hecht, senior vice president, Site &...
Read More
Press Release Oct 28, 2015
Research Triangle Park, NC, October 28, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter ended September 30, 2015. 8.3% constant currency service revenue growth compared to the third quarter of 2014 44.6% increase in diluted adjusted EPS to $0.94 per share compared to the third quarter of 2014, third quarter GAAP reported diluted EPS of $0.89 Net new business of $1.16 billion, increasing backlog to $11.75 billion as of September 30, 2015 Updating full year 2015 constant currency service revenue growth guidance to a range of 8.6% - 9.2% compared to full year 2014 and increasing diluted adjusted EPS guidance to $3.27 - $3.33 per share, representing diluted adjusted EPS growth of 21.1%...
Read More
Press Release Oct 22, 2015
RESEARCH TRIANGLE PARK, NC and DANBURY, CT, October 22, 2015 – Quintiles and IMS Health today announced a global strategic alliance that will advance the way biopharmaceutical companies generate real-world evidence (RWE) and apply critical insights to drive late-stage clinical research. With complementary strengths in real-world data management, operational delivery, advanced analytics, and scientific and therapeutic expertise, the collaboration will accelerate assessments of treatment impact and help improve patient outcomes. As healthcare stakeholders increase their focus on value, evidence of a medicine’s effectiveness and safety in real-world settings continues to be a critical component of drug development and healthcare delivery. This alliance brings together market-leading...
Read More
Press Release Oct 19, 2015
RESEARCH TRIANGLE PARK, N.C. – October 19, 2015 – Quintiles announced that Kevin Gordon, currently serving as Executive Vice President, Operations and Chief Financial Officer (CFO), has been promoted to Chief Operating Officer (COO) and that Michael McDonnell is expected to join Quintiles in December 2015 as Executive Vice President, Chief Financial Officer (CFO). Mr. Gordon will continue to serve as Quintiles CFO until Mr. McDonnell joins the company. “Kevin’s new role is recognition of the major contribution he has made to the company,” said Chief Executive Officer Tom Pike. “With Kevin as Chief Operating Officer, we are formalizing many of his activities with customers, our executives and employees. Over the past years, Kevin has increased his operational influence and is already...
Read More
Press Release Oct 15, 2015
SINGAPORE – October 16, 2015 – Citing Quintiles’ innovation, customer service and growth, Frost & Sullivan has named Quintiles as its Asia Pacific Contract Research Organization Company of the Year. “Quintiles is the clear market leader in the Asia Pacific CRO landscape,” said Rhenu Bhuller, Partner, Healthcare, Frost & Sullivan. “Asia Pacific is a strong focus area for multinational CROs and we evaluated the top five on two key factors – ‘visionary innovation and performance’ and ‘customer impact’. Quintiles scored highly in all criteria, and particularly so in ‘pioneering best practices’ and ‘addressing biopharma’s unmet needs’. “For example, Quintiles launched a dedicated medical devices unit in Asia Pacific in 2015 that leverages the expertise of Novella Clinical, a Quintiles...
Read More
Press Release Oct 14, 2015
RESEARCH TRIANGLE PARK, NC – October 14, 2015 – For the third year in a row, Quintiles has been named the industry leader in Phase I services according to respondents in Industry Standard Research’s (ISR) 2015 CRO Quality Benchmarking – Phase I Service Providers report. Quintiles also was identified as the most preferred Phase I service provider based on ISR’s survey of biopharmaceutical industry decision-makers across North America, Europe and Asia. “We are honored to be recognized once again as the industry leader in Phase I services and most preferred Phase I service provider in ISR’s 2015 report,” said Mary Westrick, Ph.D., vice president, Early Clinical Development at Quintiles. “I believe that the scientific expertise and clinical experience of Quintiles’ staff, as well as our...
Read More
Press Release Oct 12, 2015
RESEARCH TRIANGLE PARK, N.C. – October 12, 2015 – Quintiles today announced that it has been awarded the Society for Clinical Research Sites’ (SCRS) 2015 Clinical Research Organization (CRO) Eagle Award. Presented during the annual SCRS Site Solutions Summit, the award honors outstanding leadership, professionalism, integrity, passion and dedication when working with sites.  “It is a tremendous honor to be recognized for this award three years in a row,” said Jeanne Hecht, senior vice president and global head, Site & Patient Networks at Quintiles. “This award reflects Quintiles’ commitment to continually enhancing site relationships. I would like to thank our dedicated employees at Quintiles, as well as the talented individuals and teams with whom we work at investigator sites around...
Read More
Press Release Oct 02, 2015
RESEARCH TRIANGLE PARK, N.C. – October 2, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its third-quarter 2015 financial results Wednesday, October 28, 2015 prior to its quarterly earnings call at 8:00 a.m. EDT. The conference call will be accessible live, via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 710-5091 in the United States or +1 (706) 902-0591 outside the United States, approximately 15 minutes before the scheduled start of the call. An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EDT on Wednesday, October 28th. About Quintiles Quintiles (NYSE: Q) helps biopharma and other...
Read More
Press Release Sep 28, 2015
RESEARCH TRIANGLE PARK, N.C. – September 28, 2015 – Quintiles has been named the market leader in Phase IV services for the third year in a row, according to the 2015 CRO Quality Benchmarking – Phase IV Service Providers Report from Industry Standard Research (ISR). Quintiles was selected as the preferred provider among biopharmaceutical companies for Phase IV services based on a survey of 110 global biopharmaceutical representatives. In the report, Quintiles was highlighted as a leader across a number of key service quality metrics, including its service breadth, global footprint and technology that enables real-time data access delivered by its award-winning Quintiles Infosario® platform. “We are proud to be honored once again for our leadership in Phase IV services across all of our...
Read More
Press Release Sep 28, 2015
RESEARCH TRIANGLE PARK, NC – September 28, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) announced today that Annie Hai-yuan Lo, has been appointed to its Board of Directors, effective immediately. Ms. Lo will also serve as a member of the Audit Committee of the Board. Ms. Lo has more than 30 years of financial and operational experience at Johnson & Johnson, a global healthcare company, most recently serving as the Chief Financial Officer of the Worldwide Consumer & Personal Care Group from 2001 until her retirement in 2011. Ms. Lo serves as a director of Ansell Ltd., an Australian manufacturing company, and TransForce Inc., a Montreal-based transportation and logistics company. Ms. Lo received her Bachelor’s Degree in Taiwan from National Taiwan...
Read More
Press Release Aug 28, 2015
RESEARCH TRIANGLE PARK, N.C. – August 28, 2015 – Quintiles CEO Tom Pike will present at the UBS Best of Americas 2015 Conference on Friday, September 11, 2015 in London at the UBS offices. The Quintiles presentation will begin at 9:00 a.m. GMT (4:00 a.m. EDT). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors.  An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest...
Read More
Press Release Aug 05, 2015
RESEARCH TRIANGLE PARK, N.C. – August 5, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 7,000,000 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation and Temasek Life Sciences Private Limited (the “Selling Shareholders”) at a price to the public of $77.85 per share.  The price per share paid to the Selling Shareholders by the underwriter was $77.37 per share.  Quintiles did not offer any stock in this transaction and did not receive any proceeds from the sale of the shares by the Selling Shareholders. Morgan Stanley served as the sole...
Read More